drug
umeclidinium bromide
Marketedupdated 5mo agoby GlaxoSmithKline LLC
Approvedcommunity read0 votes
indications
investigational
COPD
all catalysts(0)
nothing on the calendar yet
Trials studying umeclidinium bromide
Patent cliff
source: FDA Orange Bookfirst barrier falls
Dec 18, 2027
~1.2 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (1)
- Dec 18, 2027compositionUS 74888271.2y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 8m ago
Found something off?
comments(0)
5-min edit window · permanent after that